Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 4/20 | 0.55 |
| ▸ | NPC1 | O15118 | 6/20 | 0.54 |
| ▸ | RAB9A | P51151 | 6/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.54 |
| ▸ | STAT1 | P42224 | 1/20 | 0.54 |
| ▸ | SCD | O00767 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | ALPL | P05186 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.50 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.50 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23628959 | 0.87 | GSK3B (0.54) | GSK3BNPC1RAB9ASMN1; SMN2STAT1 | |
| SCHEMBL23629027 | 0.85 | GSK3B (0.52) | GSK3BNPC1RAB9ASMN1; SMN2STAT1 | |
| SCHEMBL23628930 | 0.84 | MAPT (0.55) | GSK3BNPC1RAB9ASMN1; SMN2STAT1 | |
| SCHEMBL23628893 | 0.83 | CYP3A4 (0.66) | GSK3BNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL23629015 | 0.78 | NPC1 (0.53) | GSK3BNPC1RAB9ASMN1; SMN2STAT1 | |
| SCHEMBL2759560 | 0.78 | RAB9A (0.65) | NPC1RAB9ASMN1; SMN2SCDMEN1 | |
| SCHEMBL1064848 | 0.76 | HDAC1 (0.68) | GSK3BNPC1RAB9ASMN1; SMN2SCD | |
| SCHEMBL23628906 | 0.76 | SCD (0.52) | GSK3BNPC1RAB9ASMN1; SMN2STAT1 | |
| SCHEMBL19921646 | 0.76 | HSD17B10 (0.60) | NPC1RAB9ASMN1; SMN2STAT1ALDH1A1 | |
| SCHEMBL23628931 | 0.75 | SCD (0.51) | GSK3BNPC1RAB9ASMN1; SMN2STAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12258342-B2 | Class of DNA gyrase and/or topoisomerase IV inhibitors with activity against gram-positive and gram-negative bacteria | UNIVERZA V LJUBLJANI (SI) | 2025-03-25 | — | — | US | disclosed |
| US-20210323957-A1 | NEW CLASS OF DNA GYRASE AND/OR TOPOISOMERASE IV INHIBITORS WITH ACTIVITY AGAINST GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | UNIVERZA V LJUBLJANI (SI) | 2021-10-21 | — | — | US | disclosed |
| EP-3847172-A1 | NEW CLASS OF DNA GYRASE AND/OR TOPOISOMERASE IV INHIBITORS WITH ACTIVITY AGAINST GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | Univerza v Ljubljani (SI) | 2021-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323957-A1 | NEW CLASS OF DNA GYRASE AND/OR TOPOISOMERASE IV INHIBITORS WITH ACTIVITY AGAINST GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | TOP1, TOP2A, TOP2B | GSK3B 500/4885NPC1 4573/4885RAB9A 3897/4885 |
| US-12258342-B2 | Class of DNA gyrase and/or topoisomerase IV inhibitors with activity against gram-positive and gram-negative bacteria | TOP1, TOP2A, TOP2B | GSK3B 317/4885NPC1 4546/4885RAB9A 3924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.